Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
BookmarkRelated Content
-
Jackie JamesJackie is the mother of Anna who has Muc...
-
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
-
Sanfilippo Children’s Foundation – FacebookSanfilippo Children's Foundation is a no...
-
A Guide to Understanding MPS III (Sanfilippo Syndrome)MPS III belongs to a group of inherited ...
-
Hurler Syndrome Treatment Market Research Prophesied to Grow at a Faster Pace By 2026This Hurler Syndrome Treatment market re...
-
Cure Sanfilippo FoundationCure Sanfilippo Foundation is a Not-for-...
-
Surgical Management of an Aortic Root Dilatation in a Patient Suffering From Hunter SyndromeHunter syndrome is a rare disease leadin...
Powered by
